Monoclonal Antibody Therapeutics 2009-2024
Monoclonal antibodies achieved total sales of nearly $32bn in 2008 and have grown rapidly to command over 30% of the global biologic drug market. Significant opportunities are expected for further commercial growth from 2009 to 2024, as shown in this report, Monoclonal Antibody Therapeutics 2009-2024. New technologies will be an important growth driver. Intensive R&D activity is producing an exciting antibody pipeline, filled with novel monoclonal antibodies, antibody fragments and antibody-drug conjugates. Furthermore, monoclonal antibodies already on the market have scope for additional development. In particular, the application of monoclonal antibodies in new therapeutic areas is expected outside the currently-established fields.
At the same time, challenges and changes lie ahead. Increased competition for antibody targets and patient populations, pricing pressures from governments and other healthcare payers, patent expiry for high-revenue monoclonal antibodies and the spectre of biosimilar monoclonal antibodies will come to the fore during the period 2009 to 2024.
What will be the characteristics of drugs that will succeed Avastin and Remicade, becoming the blockbusters of the future? What are the potential applications and prospects for antibody fragments? Which pipeline drugs are the ones to watch? Our completely updated report - packed with 140 tables and figures – will show you the outlook for this dynamic sector of the pharmaceutical market.
Comprehensive analysis of the monoclonal antibody therapeutics market
Monoclonal Antibody Therapeutics 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are also three detailed interviews with authorities on the sector in this 200+ page report. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.
Why you should buy this report
By ordering Monoclonal Antibody Therapeutics 2009-2024 you will:
- Find out the market prognosis for the global monoclonal antibody therapeutics market and for the relevant markets in oncology, autoimmune disorders and other therapeutic areas from 2009 to 2024
- Receive comprehensive market forecasts and competitive analyses for leading monoclonal antibodies, including Rituximab, Avastin, Herceptin, Erbitux, Remicade, Humira, Xolair, Tysabri, Lucentis and Synagis, and for potential blockbusters of the future
- Read expert views from key-opinion leaders in the monoclonal antibody field, with full interview transcripts provided
- Examine strengths, weakness, opportunities and threats (SWOT) facing major stakeholders in the industry, including the prospects for biosimilar monoclonal antibodies
- Discover market forecasts for the leading monoclonal antibody country markets and for the emerging markets of China and India
- Analyse the monoclonal antibody therapeutics pipeline, especially for late-stage candidates, including the prospects for antibody fragments and antibody-drug conjugates.
Table of Contents
1 Executive Summary
2 Introduction to Monoclonal Antibodies
- 2.1 Antibodies
- 2.1.1 Function of Antibodies
- 2.1.2 Structure of Antibodies
- 2.2 Monoclonal Antibody Therapeutics
- 2.2.1 Polyclonal and Monoclonal Antibodies
- 2.2.2 Murine Monoclonal Antibodies
- 2.2.3 Chimeric and Humanised Monoclonal Antibodies
- 2.2.4 Fully-Human Monoclonal Antibodies
- 2.2.5 Currently-Approved Monoclonal Antibody Therapeutics
3 The Global Monoclonal Antibodies Market, 2009-2024
- 3.1 Monoclonal Antibodies: Market Overview
- 3.1.1 Size of Monoclonal Antibody Market in 2008
- 3.1.2 Monoclonal Antibodies: Revenue Analysis by Therapeutic Area, 2008
- 3.1.3 Leading Monoclonal Antibodies: Revenue Analysis, 2008
- 3.1.4 Monoclonal Antibodies: Revenue Analysis by Type, 2008
- 3.1.5 Monoclonal Antibodies: Revenue Analysis by Company, 2008
- 3.1.6 Global Monoclonal Antibody Market Forecast, 2009-2014
- 3.1.7 Monoclonal Antibodies Sales Forecast, 2014-2024
- 3.2 The Oncology Monoclonal Antibodies Market
- 3.2.1 Leading Oncology Monoclonal Antibodies: Revenue Analysis, 2008
- 3.2.2 Oncology Monoclonal Antibodies: Revenue Analysis by Type, 2008
- 3.2.3 Oncology Monoclonal Antibodies: Revenue Analysis by Company, 2008
- 3.2.4 Continuing High Growth: Oncology Monoclonal Antibodies, 2009-2014
- 3.2.5 Oncology Monoclonal Antibodies Sales Forecast, 2014-2024
- 3.3 MabThera/Rituxan
- 3.3.1 MabThera/Rituxan: The First Blockbuster Monoclonal Antibody
- 3.3.2 MabThera/Rituxan Revenue Analysis, 2008
- 3.3.3 MabThera/Rituxan Market Forecast, 2009-2014
- 3.3.4 MabThera/Rituxan Long-Term Prospects, 2014-2024
- 3.3.5 New Oncology Growth Areas for MabThera/Rituxan, 2009-2014
- 3.3.6 Intensifying Competition: MabThera/Rituxan in Oncology, 2014-2024
- 3.4 Avastin
- 3.4.1 Avastin: A Cancer Blockbuster Set To Reach $10bn
- 3.4.2 Avastin Revenue Analysis, 2008
- 3.4.3 Avastin 2009-2014: 'a Pipeline-In-One'
- 3.4.4 The Competitive Landscape for Avastin, 2009-2014
- 3.4.5 Avastin Market Forecast, 2009-2014
- 3.4.6 Outlook for Avastin: Sales Forecast, 2014-2024
- 3.5 Herceptin
- 3.5.1 Herceptin Successfully Targets HER2-Positive Patients
- 3.5.2 Herceptin Revenue Analysis, 2008
- 3.5.3 Herceptin Market Forecast, 2009-2014
- 3.5.4 Increased Competition for Herceptin, 2014-2024
- 3.6 Erbitux
- 3.6.1 Erbitux's Oncology Indications
- 3.6.2 Erbitux Revenue Analysis, 2008
- 3.6.3 Opportunity in Head and Neck Cancer and New Indications for Erbitux
- 3.6.4 Erbitux Sales Forecast, 2009-2024
- 3.7 Other Oncology Monoclonal Antibodies
- 3.7.1 Vectibix
- 3.7.2 Vectibix Revenue Analysis, 2008
- 3.7.3 Campath/MabCampath
- 3.7.4 Campath/MabCampath Revenue Analysis
- 3.7.5 Mylotarg
- 3.7.6 Zevalin
- 3.7.7 Bexxar
- 3.7.8 TheraCIM (Nimotuzumab)
- 3.7.9 Removab
- 3.8 The Autoimmune Disorder Monoclonal Antibodies Market
- 3.8.1 Leading Autoimmune Disorder Monoclonal Antibodies: Revenue Analysis, 2008
- 3.8.2 Autoimmune Disorder Monoclonal Antibodies: Revenue Analysis by Type, 2008
- 3.8.3 Autoimmune Disorder Monoclonal Antibodies: Revenue Analysis by Company, 2008
- 3.8.4 Humira and Novel Antibodies Drive Autoimmune Monoclonal Market, 2009-2014
- 3.8.5 Autoimmune Disorder Monoclonal Antibodies Sales Forecast, 2014-2024
- 3.9 Remicade
- 3.9.1 Remicade: Leading Anti-TNF Drug
- 3.9.2 Remicade Revenue Analysis, 2008
- 3.9.3 Remicade's Competitors
- 3.9.4 Imminent Increase in Competition for Remicade
- 3.9.5 Remicade Market Forecast, 2009-2014
- 3.9.6 Remicade Market Forecast, 2015-2025
- 3.10 Humira
- 3.10.1 Humira: First Fully-Human Monoclonal Antibody on Market
- 3.10.2 Humira Revenue Analysis, 2008
- 3.10.3 Humira's Market Potential, 2009-2014
- 3.10.4 Humira Sales Forecast, 2015-2024
- 3.11 Novel Anti-TNF Monoclonal Antibodies
- 3.11.1 Cimzia: Newly-Approved Fully-Human Monoclonal Antibody
- 3.11.2 Cimzia Sales Forecast, 2009-2024
- 3.11.3 Simponi
- 3.11.4 Simponi Sales Forecast, 2009-2024
- 3.12 MabThera/Rituxan for Autoimmune Disorders
- 3.12.1 MabThera/Rituxan: Not Just for Oncology
- 3.12.2 Raft of Competitors for MabThera/Rituxan in Autoimmune Disorders, 2009-2024
- 3.13 Xolair
- 3.13.1 Genentech's Asthma Monoclonal Antibody: Xolair
- 3.13.2 Xolair Revenue Analysis, 2008
- 3.13.3 Xolair Sales Forecast, 2009-2014
- 3.14 Tysabri
- 3.14.1 Tysabri
- 3.14.2 Tysabri Revenue Analysis, 2008
- 3.14.3 Tysabri Sales Forecast, 2009-2024
- 3.15 Other Autoimmune Disorder Monoclonal Antibodies
- 3.15.1 Soliris
- 3.15.2 Soliris Revenue Analysis, 2008
- 3.15.3 Raptiva
- 3.15.4 Raptiva Revenue Analysis, 2008
- 3.15.5 Raptiva Withdrawn from Market in 2009
- 3.15.6 Simulect
- 3.15.7 Actemra/RoActemra
- 3.15.8 Zenapax
- 3.15.9 Orthoclone OKT3
- 3.15.10 Stelara
- 3.15.11 Simponi
- 3.16 Other Monoclonal Antibodies (Non-Oncology/Autoimmune Disorders)
- 3.16.1 Other Leading Monoclonal Antibodies: Revenue Analysis, 2008
- 3.16.2 Other Monoclonal Antibodies Sales Forecast, 2009-2024
- 3.17 Lucentis
- 3.17.1 Lucentis: Serendipitous Antibody Fragment for Ophthalmology
- 3.17.2 Lucentis Revenue Analysis, 2008
- 3.17.3 Impact of Off-Label Avastin on Lucentis, 2009-2024
- 3.17.4 Lucentis Sales Forecast, 2009-2014
- 3.17.5 Lucentis Sales Forecast, 2014-2024
- 3.18 Synagis
- 3.18.1 Synagis: Sole Blockbuster Respiratory Disorder Monoclonal Antibody
- 3.18.2 Synagis Revenue Analysis, 2008
- 3.18.3 Synagis/Motavizumab Market Forecast, 2009-2024
- 3.19 ReoPro
- 3.19.1 ReoPro: Cardiovascular Monoclonal Antibody Fragment
- 3.19.2 ReoPro Revenue Analysis, 2008
4 Monoclonal Antibody Country Markets
- 4.1 Regional Overview
- 4.1.1 Top Eight Monoclonal Antibody Country Markets, 2008
- 4.1.2 US, Canada, France, Germany, Spain, Italy, UK, Japan, China & India Monoclonal Antibody Market Forecasts, 2009-2024
- 4.2 The US Monoclonal Antibody Therapeutics Market
- 4.2.1 US Market in 2008
- 4.2.2 US Monoclonal Antibodies Sales Forecast, 2009-2024
- 4.3 European Monoclonal Antibody Therapeutics Market
- 4.4 Monoclonal Antibodies in Emerging Markets
5 The Monoclonal Antibody Therapeutic Pipeline
- 5.1 Late-Stage Oncology Pipeline: Additional and Expanded Indications
- 5.1.1 Avastin
- 5.1.2 MabThera/Rituxan
- 5.1.3 Erbitux
- 5.1.4 Tysabri
- 5.2 Late-Stage Oncology Pipeline: Novel Entities
- 5.2.1 Arzerra (Ofatumumab)
- 5.2.2 Farletuzumab (MORAb-003)
- 5.2.3 Figitumumab (CP-751871)
- 5.2.4 Galiximab
- 5.2.5 Ipilimumab
- 5.2.6 Ramucirumab (IMC 1121B)
- 5.2.7 Rencarex (WX-G250)
- 5.2.8 Zalutumumab (HuMax-EGFr)
- 5.2.9 Lumiliximab
- 5.2.10 Pertuzumab (R1273)
- 5.3 Late-Stage Autoimmune Disorder Pipeline: Additional and Expanded Indications
- 5.3.1 Actemra/RoActemra
- 5.3.2 MabThera/Rituximab
- 5.3.3 Alemtuzumab for Multiple Sclerosis
- 5.4 Late-Stage Autoimmune Disorder Pipeline: New Entities
- 5.4.1 Ilaris (Canakinumab)
- 5.4.2 Stelara (Ustekinumab)
- 5.4.3 Simponi (Golimumab)
- 5.4.4 Bapineuzumab ((AAB-001)
- 5.4.5 Benlysta (Belimumab)
- 5.4.6 ABT-874
- 5.4.7 Mycograb (Efungumab)
- 5.4.8 Ocrelizumab (R1594)
- 5.4.9 Otelixizumab (TRX4)
- 5.4.10 Reslizumab (Reslizumab)
- 5.4.11 Solanezumab
- 5.4.12 Tanezumab (PF-4383119)
- 5.4.13 Teplizumab (MGA031)
- 5.4.14 Vedolizmab (MLN0002)
- 5.5 Other Monoclonal Antibodies Pipeline (Non-Oncology/Autoimmune Disorders)
- 5.5.1 Denosumab: Promising Bone Disorder Pipeline Drug
- 5.5.2 Denosumab: Competitor Analysis
- 5.5.3 Motavizumab
- 5.5.4 Bosatria (Mepolizumab)
- 5.5.5 Lucentis
- 5.6 Early Stage Pipeline: Antibody Fragments
- 5.6.1 Development and Potential of Antibody Fragments
- 5.6.2 Ablynx's Nanobodies: Future Cash Llama?
- 5.6.3 Domantis' Domain Fragments
- 5.6.4 Genmab's UniBodies
- 5.6.5 ESBATech
- 5.6.6 Affimed's TandAbs and Flexibodies
- 5.6.7 Micromet's BiTE Antibody Platform
- 5.7 Early Stage Pipeline: Antibody-Drug Conjugates
- 5.7.1 The Future of Conjugated Antibodies
- 5.7.2 Seattle Therapeutics
- 5.7.3 ImmunoGen's TAP Technology
- 5.7.4 Neuradiab
6 Issues Affecting the Monoclonal Antibodies Market
- 6.1 SWOT Chart for the Monoclonal Antibodies Industry
- 6.2 Strengths
- 6.2.1 Monoclonal Antibodies Have a Wide Range of Specific Targets
- 6.2.2 Chronic and Niche Diseases Generate High Revenues
- 6.2.3 Rich Pipeline and Manufacturing Improvements
- 6.2.4 Lower Risk of Adverse Events for Oncology Monoclonal Antibodies
- 6.3 Weaknesses
- 6.3.1 Biosimilar Monoclonal Antibodies
- 6.3.2 Future Prospects for Biosimilar Monoclonal Antibodies
- 6.3.3 High Development Cost Limits Growth
- 6.3.4 Injections are the Main Mode of Administration
- 6.3.5 The Challenge of Immunogenicity Still Looms Large
- 6.3.6 Competition is Fierce for Many Targets
- 6.3.7 Insufficient Efficacy of Oncology Monoclonal Antibodies as Monotherapy
- 6.4 Opportunities
- 6.4.1 Increasing Cancer Prevalence
- 6.4.2 Autoimmune Disorder Prevalence and Under-Treatment
- 6.5 Threats
- 6.5.1 Lack of Reimbursement for Monoclonal Antibodies
- 6.5.2 High Profile Safety Cases Increase Regulatory Concerns
- 6.5.3 Current Financial Limitations in Research and Development
7 Interviews with Monoclonal Antibody Industry Key Opinion Leaders
- 7.1 Dr Debbie Law, Chief Scientific Officer, and Eva-Lotta Allan, Chief Business Office, Ablynx
- 7.1.1 Future Prospects for Full-Size Monoclonal Antibodies, Conjugated Antibodies and Fragment Antibodies
- 7.1.2 Nanobodies
- 7.1.3 Immunogenicity of Nanobodies
- 7.1.4 Ablynx's Anti-Thrombotic Nanobody Pipeline
- 7.1.5 Anti-TNF and Anti-RANKL Nanobodies
- 7.1.6 Potential Advantages of Anti-Thrombotic Nanobodies
- 7.1.7 Multi-Valency and Multi-Specificity: Nanobodies as Building Blocks
- 7.1.8 New Delivery Methods
- 7.1.9 Future Commercial Direction of Monoclonal Antibody and Antibody Fragments
- 7.2 Janice M. Reichert, PhD, Senior Research Fellow at Tufts University
- 7.2.1 Major Challenges and Opportunities for Monoclonal Antibody Cancer Therapeutics
- 7.2.2 Side-Effects of Monoclonal Antibodies for Cancer
- 7.2.3 Future Developments and Pipelines
- 7.2.4 The Effect of Biosimilars
- 7.3 David Blakey, PhD, Chief Scientist, Cancer & Infection Research Area, AstraZeneca
- 7.3.1 The Future of Humanised and Fully-Human Antibodies
- 7.3.2 Therapeutic Antibody Fragments Versus Full-Length Antibodies
- 7.3.3 Major Opportunities in Monoclonal Antibody Cancer Therapeutics
8 Conclusions
- 8.1 Monoclonal Antibodies Account for Over 30% of Biologic Drug Revenues
- 8.2 Future Prospects for the Monoclonal Antibody Market
- 8.3 The Monoclonal Antibody Pipeline
- 8.4 Recent High Growth Rates Set to Continue to 2014
- 8.5 Market Forecast, 2014-2024
- 8.6 Expansion into New Markets
- 8.7 Future Outlook
List of Tables
- Table 2.1 Monoclonal Antibody Technology
- Table 2.2 Modes of Action for Monoclonal Antibody Therapeutics
- Table 2.3 Monoclonal Antibody Therapeutics Approved by US FDA, 1986-2003
- Table 2.4 Monoclonal Antibody Therapeutics Approved by US FDA, 2003-2009
- Table 3.1 Monoclonal Antibody Sales by Therapeutic Area, 2008
- Table 3.2 Sales of Leading Monoclonal Antibodies, 2008
- Table 3.3 Monoclonal Antibody Sales by Technology Type, 2008
- Table 3.4 Sales of Monoclonal Antibodies by Antibody Type, 2008
- Table 3.5 Sales of Monoclonal Antibodies by Marketing Company, 2008
- Table 3.6 Monoclonal Antibody Therapeutic Market, Drivers & Restraints, 2009-2024
- Table 3.7 Total, Oncology, Autoimmune Disorder and Other Monoclonal Antibodies Sales Forecasts, 2009-2014
- Table 3.8 Total, Oncology, Autoimmune Disorder and Other Monoclonal Antibodies Sales Forecasts, 2015-2024
- Table 3.9 Sales of Leading Oncology Monoclonal Antibodies, 2008
- Table 3.10 Sales by Technology Type, Oncology Monoclonal Antibodies, 2008
- Table 3.11 Sales by Antibody Type, Oncology Monoclonal Antibodies, 2008
- Table 3.12 Sales by Marketing Company, Oncology Monoclonal Antibodies, 2008
- Table 3.13 Oncology Monoclonal Antibodies, Drivers & Restraints, 2009-2024
- Table 3.14 MabThera/Rituxan, Avastin, Herceptin, Erbitux & Total Oncology Monoclonal Antibodies Sales Forecasts, 2009-2014
- Table 3.15 MabThera/Rituxan, Avastin, Herceptin, Erbitux & Total Oncology Monoclonal Antibodies Sales Forecasts, 2015-2024
- Table 3.16 MabThera/Rituxan Sales by Marketing Company, 2008
- Table 3.17 MabThera/Rituxan Sales by Country, 2008
- Table 3.18 MabThera/Rituxan Total, Oncology & Autoimmune Disorder Sales Forecast, 2009-2014
- Table 3.19 MabThera/Rituxan Total, Oncology & Autoimmune Disorder Sales Forecast, 2015-2024
- Table 3.20 MabThera/Rituxan, Drivers & Restraints, 2009-2024
- Table 3.21 Avastin Sales by Marketing Company, 2008
- Table 3.22 Avastin Sales by Country, 2008
- Table 3.23 Avastin, Drivers & Restraints, 2009-2024
- Table 3.24 Herceptin Sales by Marketing Company, 2008
- Table 3.25 Herceptin Sales by Country, 2008
- Table 3.26 Herceptin, Drivers & Restraints, 2009-2024
- Table 3.27 Erbitux Sales by Marketing Company, 2008
- Table 3.28 Erbitux Sales by Country, 2008
- Table 3.29 Erbitux, Drivers & Restraints, 2009-2024
- Table 3.30 Major Nimotuzumab Markets, 2009
- Table 3.31 Sales of Leading Autoimmune Disorder Monoclonal Antibodies, 2008
- Table 3.32 Sales by Technology Type, Autoimmune Disorder Monoclonal Antibodies, 2008
- Table 3.33 Sales by Antibody Type, Autoimmune Disorder Monoclonal Antibodies, 2008
- Table 3.34 Sales by Marketing Company, Autoimmune Disorder Monoclonal Antibodies, 2008
- Table 3.35 Autoimmune Disorder Monoclonal Antibodies, Drivers & Restraints, 2009-2024
- Table 3.36 Remicade, Humira, Simponi, Cimzia & Total Autoimmune Disorder Monoclonal Antibodies Sales Forecasts, 2009-2014
- Table 3.37 Remicade, Humira, Simponi, Cimzia & Total Autoimmune Disorder Monoclonal Antibodies Sales Forecasts, 2015-2024
- Table 3.38 Remicade Sales by Marketing Company, 2008
- Table 3.39 Remicade Sales by Country, 2008
- Table 3.40 Remicade, Drivers & Restraints, 2009-2024
- Table 3.41 Approved Indications for Humira in the US
- Table 3.42 Humira Sales by Marketing Company, 2008
- Table 3.43 Humira Sales by Country, 2008
- Table 3.44 Humira, Drivers & Restraints, 2009-2024
- Table 3.45 Cimzia, Drivers & Restraints, 2009-2024
- Table 3.46 Simponi, Drivers & Restraints, 2009-2024
- Table 3.47 MabThera/Rituxan (Autoimmune Indications), Xolair & Tysabri Sales Forecasts, 2009-2014
- Table 3.48 MabThera/Rituxan (Autoimmune Indications), Xolair, & Tysabri Sales Forecasts, 2015-2024
- Table 3.49 Tysabri Sales by Country, 2008
- Table 3.50 Sales of Leading Other Monoclonal Antibodies (Non-Oncology/Autoimmune Disorders), 2008
- Table 3.51 Lucentis, Synagis/Motavizumab and Other Non-Oncology/Autoimmune Disorder Monoclonal Antibodies Sales Forecasts, 2009-2014
- Table 3.52 Lucentis, Synagis/Motavizumab and Other Non-Oncology/Autoimmune Disorder Monoclonal Antibodies Sales Forecasts, 2015-2024
- Table 3.53 Lucentis Sales by Marketing Company, 2008
- Table 3.54 Lucentis Sales by Country, 2008
- Table 3.55 Drivers and Restraints on Lucentis Revenues, 2009-2014
- Table 3.56 Synagis Sales by Marketing Company, 2008
- Table 3.57 Synagis Sales by Country, 2008
- Table 4.1 Leading Eight Monoclonal Antibody Therapeutics Markets, 2008
- Table 4.2 US, Canada, France, Germany, Spain, Italy, UK, Japan, China & India Monoclonal Antibody Market Forecasts, 2009-2024
- Table 4.3 US Monoclonal Antibody Sales by Therapeutic Area, 2008
- Table 4.4 Leading Ten US Monoclonal Antibodies, 2008
- Table 5.1 Oncology Pipeline: Additional Indications for Avastin
- Table 5.2 Oncology Pipeline: Additional Indications for Approved Drugs (Other than Avastin)
- Table 5.3 Oncology Pipeline: Selected New Entities in Phase III or Regulatory/Submission
- Table 5.4 Oncology Pipeline: Selected New Entities in Phase II, Part 1
- Table 5.5 Oncology Pipeline: Selected New Entities in Phase II, Part 2
- Table 5.6 Autoimmune Disorders Pipeline: Additional Indications for Approved Drugs
- Table 5.7 Autoimmune Disorder Pipeline: Selected New Entities in Phase III/Regulatory Submission: Part 1
- Table 5.8 Autoimmune Disorder Pipeline: Selected New Entities in Phase III/Regulatory Submission: Part 2
- Table 5.9 Autoimmune Disorder Pipeline: Selected New Entities in Phase II
- Table 5.10 Pipeline for Other Monoclonal Antibodies (Non-Oncology/Autoimmune Disorders)
- Table 5.11 Antibody Fragment Pipeline
- Table 5.12 Antibody-Cytotoxic Drug Conjugate Pipeline: Part 1
- Table 5.13 Antibody-Cytotoxic Drug Conjugate Pipeline: Part 2
- Table 6.1 SWOT Chart for the Monoclonal Antibody Therapeutics Industry, 2009-2024
- Table 6.2 Monoclonal Antibody Targets
- Table 6.3 Expected Patent Expiries for Monoclonal Antibodies
- Table 6.4 Biosimilar Monoclonal Antibodies in Development
List of Figures
- Figure 2.1 Antibody Structure
- Figure 3.1 Monoclonal Antibody Therapeutic Area Market Share, 2008
- Figure 3.2 Leading Monoclonal Antibodies Market Share, 2008
- Figure 3.3 Monoclonal Antibody Technology Type Market Share, 2008
- Figure 3.4 Monoclonal Antibody Type Market Share, 2008
- Figure 3.5 Monoclonal Antibody Marketing Company Market Share, 2008
- Figure 3.6 Total Monoclonal Antibodies Sales Forecast, 2009-2024
- Figure 3.7 Oncology, Autoimmune Disorder and Other Monoclonal Antibodies Sales Forecasts, 2009-2024
- Figure 3.8 Oncology, Autoimmune Disorder and Other Monoclonal Antibodies Market Share, 2009-2024
- Figure 3.9 Leading Oncology Monoclonal Antibodies Market Share, 2008
- Figure 3.10 Technology Type Market Share, Oncology Monoclonal Antibodies, 2008
- Figure 3.11 Antibody Type Market Share, Oncology Monoclonal Antibodies, 2008
- Figure 3.12 Marketing Company Market Share, Oncology Monoclonal Antibodies, 2008
- Figure 3.13 Total Oncology Monoclonal Antibodies Sales Forecast, 2009-2024
- Figure 3.14 MabThera/Rituxan, Avastin, Herceptin and Erbitux & Other Oncology Monoclonal Antibodies Market Share, 2009-2024
- Figure 3.15 MabThera/Rituxan Marketing Company Market Share, 2008
- Figure 3.16 MabThera/Rituxan Country Market Share, 2008
- Figure 3.17 MabThera/Rituxan Total, Oncology & Autoimmune Disorder Sales Forecast, 2009-2024
- Figure 3.18 Avastin Marketing Company Market Share, 2008
- Figure 3.19 Avastin Country Market Share, 2008
- Figure 3.20 Avastin Sales Forecast, 2009-2024
- Figure 3.21 Herceptin Marketing Company Market Share, 2008
- Figure 3.22 Herceptin Country Market Share, 2008
- Figure 3.23 Herceptin Sales Forecast, 2009-2024
- Figure 3.24 Erbitux Marketing Company Market Share, 2008
- Figure 3.25 Erbitux Sales Country Market Share, 2008
- Figure 3.26 Erbitux Sales Forecast, 2009-2024
- Figure 3.27 Leading Autoimmune Disorder Monoclonal Antibodies Market Share, 2008
- Figure 3.28 Technology Type Market Share, Autoimmune Disorder Monoclonal Antibodies, 2008
- Figure 3.29 Antibody Type Market Share, Autoimmune Disorder Monoclonal Antibodies, 2008
- Figure 3.30 Marketing Company Market Share, Autoimmune Disorder Monoclonal Antibodies, 2008
- Figure 3.31 Total Autoimmune Disorder Monoclonal Antibodies Sales Forecast, 2009-2024
- Figure 3.32 Remicade, Humira, Simponi, & Other Autoimmune Disorder Monoclonal Antibodies Market Share, 2009-2024
- Figure 3.33 Remicade Marketing Company Market Share, 2008
- Figure 3.34 Remicade Country Market Share, 2008
- Figure 3.35 Remicade Sales Forecast, 2009-2024
- Figure 3.36 Humira Marketing Company Market Share, 2008
- Figure 3.37 Humira Country Market Share, 2008
- Figure 3.38 Humira Sales Forecast, 2009-2024
- Figure 3.39 Cimzia Sales Forecast, 2009-2024
- Figure 3.40 Simponi Sales Forecast, 2009-2024
- Figure 3.41 Xolair Sales Forecast, 2009-2024
- Figure 3.42 Tysabri Country Market Share, 2008
- Figure 3.43 Tysabri Sales Forecast, 2009-2024
- Figure 3.44 Total Non-Oncology/Autoimmune Disorder Monoclonal Antibodies Sales Forecast, 2009-2024
- Figure 3.45 Lucentis Marketing Company Market Share, 2008
- Figure 3.46 Lucentis Country Market Share, 2008
- Figure 3.47 Lucentis Sales Forecast, 2009-2024
- Figure 3.48 Synagis Marketing Company Market Share, 2008
- Figure 3.49 Synagis Country Market Share, 2008
- Figure 3.50 Synagis/Motavizumab Sales Forecast, 2009-2024
- Figure 4.1 Leading Eight Monoclonal Antibody Therapeutics Markets, 2008
- Figure 4.2 US, Canada, France, Germany, Spain, Italy, UK, Japan, China & India Monoclonal Antibody Market Forecasts, 2009-2024
- Figure 4.3 US Monoclonal Antibody Sales by Therapeutic Area, 2008
- Figure 4.4 Leading Ten US Monoclonal Antibodies, 2008
- Figure 4.5 US Monoclonal Antibodies Sales Forecast, 2009-2024
- Figure 5.1 Antibody Fragment Types
- Figure 8.1 World Monoclonal Antibody Therapeutics Market Forecast, 2009-2024
Other users found this report page using the following search terms: mAb antibodies antibody 2009 sales antibody monoclonal market antibodies herceptin patent india expiry
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.